- Epitalon is not approved by the FDA for any use, and it is not on the section 503A bulk drug substances list. Nothing in the 2026 policy changes either fact.
- Under the HHS enforcement discretion policy issued on October 28, 2026 (Federal Register notice of availability published October 30, 2026, docket HHS-OASH-2026-0496), HHS states that it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds epitalon acetate for subcutaneous or intramuscular injection, dispensed in intermittent courses, when all of the listed circumstances are present.
- Those circumstances include a valid prescription for an individually identified patient, a single active ingredient per preparation (so no blends), an original active ingredient manufacturer registered with the FDA and compliant with CGMP whose physical site appears on the certificate of analysis, a certificate meeting the conditions set out in Appendix B, reporting of serious adverse events and product quality problems to the FDA, and the label statement "This is a compounded drug product. Not for resale."
- The only delivery device the policy allows to be co-packaged with or to contain the preparation is a 510(k) cleared syringe, which on a plain reading of the text leaves pens and other delivery systems outside the policy.
- This is enforcement discretion, not approval and not a listing. It is interim, it lasts only until a final rule decides whether each substance goes on the 503A list, and HHS states it may revisit the policy if a safety signal or a product quality issue arises.
- FDA's own Center for Drug Evaluation and Research had recommended against adding epitalon to the 503A list. The policy does not cover research use only material, does not cover 503B outsourcing facilities, and has no effect outside the United States.
Is epitalon approved by the FDA?
No. Epitalon, the synthetic tetrapeptide Ala-Glu-Asp-Gly (also written epithalon or AEDG peptide), holds no marketing approval in the United States. There is no approved new drug application and no approved biologics license application for it, for any indication, in any form. It is also absent from the section 503A list of bulk drug substances that pharmacies may lawfully use in compounding, a list the FDA establishes by regulation. Any page that presents an "epitalon prescription" as the equivalent of a prescription for an approved medicine is describing something that does not exist.
That position was reinforced, not softened, by the regulatory record of 2026. When the FDA reviewed nominations for the 503A list, its Center for Drug Evaluation and Research (CDER) concluded that the lack of evidence of effectiveness and the lack of safety information for both epitalon free base and epitalon acetate weighed against adding either to the list. At the Pharmacy Compounding Advisory Committee meeting of July 23 and 24, 2026, a majority of the committee nonetheless voted in favor of inclusion. Advisory committee votes are recommendations only and do not bind the agency, and no final rule has placed epitalon on the list.
The underlying literature explains why the agency's reviewers were unconvinced. Most published work on the AEDG tetrapeptide is preclinical, much of it from a single research tradition, and a 2025 review in the International Journal of Molecular Sciences that gathered this body of work still describes the properties as promising rather than established in humans. For the general scientific picture, including what the peptide is and what the laboratory evidence does and does not show, see our epithalon guide. This article deliberately stays on a narrower question: what the United States prescription and pharmacy compounding route actually consists of.
One more distinction matters before going further. A compounded preparation is never an FDA-approved product. Section 503A describes conditions under which a compounded human drug product is exempt from certain requirements of the Federal Food, Drug, and Cosmetic Act, including premarket approval, CGMP manufacturing requirements and some labeling requirements. Exemption from review is not the same thing as having passed review.
This article is for educational purposes only. It is not medical advice, and it contains no amounts, schedules or preparation instructions. Any decision about a prescribed product belongs to you and a qualified healthcare professional.
What exactly did HHS announce in October 2026?
On October 28, 2026, the Department of Health and Human Services issued a document titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." A notice announcing its availability was published in the Federal Register on October 30, 2026 under docket number HHS-OASH-2026-0496, with written comments accepted through Regulations.gov until November 13, 2026. The policy document and its appendices sit on the HHS website; the two primary sources are linked at the end of this article and are the only documents that should be relied on for the wording.
The policy covers six peptide bulk drug substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Its mechanism is narrow and specific. HHS states that where all of the circumstances described in the policy are present, it does not intend to take enforcement action against covered compounders, namely state-licensed pharmacies, federal facilities and licensed physicians, for compounding a drug product using one of those substances. Enforcement discretion is a statement of agency intent. It does not amend the statute, it does not create a right, and it does not make the resulting product lawful in the way an approval would.
Appendix B is the substance-specific part of the document and the part that matters for this topic. For epitalon acetate, it describes subcutaneous or intramuscular injectable forms that are dispensed in intermittent courses and compounded from active ingredient accompanied by a certificate of analysis meeting the conditions of the policy. Appendix B also records, for each substance, that CDER had recommended against addition to the 503A list while the advisory committee voted in favor. In other words, the appendix that opens the door also documents the scientific objection.
Appendix B additionally fixes the chemical identity of what may be used. Epitalon acetate is identified with the molecular formula C₁₄H₂₂N₄O₉ · CH₃COOH, a molecular weight of 450.40 g/mol and the sequence H-Ala-Glu-Asp-Gly-OH · CH₃COOH. A different salt form, a different sequence or an unspecified "epitalon" material is not what the appendix describes.
Because HHS opened a comment docket, the content of the policy may evolve. Readers who want the current text should consult the Federal Register notice and the HHS appendix directly rather than any summary, including this one.
Who may compound epitalon acetate under the policy?
The policy addresses compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Three categories of compounder are named: a state-licensed pharmacy, a federal facility, and a licensed physician. Anyone outside those categories is outside the policy, whatever they call themselves and whatever paperwork they produce.
Section 503A compounding is patient-specific by design. It presupposes a valid prescription for an individually identified patient, written by a practitioner licensed to prescribe, in the course of a professional relationship. That is the first practical consequence for anyone reading this page: the only route the policy contemplates begins with a clinician who examines a specific person, documents a reason, and writes a prescription for that person. There is no version of this policy in which a consumer orders a vial and the policy covers it.
The second consequence is a limit on scale. The 503A framework is not a manufacturing authorization, and the policy does not convert a pharmacy into a producer. Large-scale preparation, stocking for general distribution and resale are not what is being described, which is also why the required label statement mentions resale explicitly.
Finally, state law still applies in full. A state board of pharmacy, a state medical board or a state statute may restrict or prohibit compounding of an unapproved substance regardless of what a federal agency says about its own enforcement intentions. Federal enforcement discretion does not pre-empt state regulators, nor does it shield anyone from professional discipline or civil liability. The broader question of how jurisdictions differ is covered in our overview of peptide legality.
Which conditions must all be met?
The policy lists ten circumstances, and HHS frames them conjunctively: enforcement discretion is described as applying where all of them are present, not most of them. A preparation that satisfies nine conditions is simply outside the policy. The table below summarizes the conditions that a patient or a prescriber can actually check, in the terms the policy uses.
| Condition | What it means in practice |
|---|---|
| Valid prescription | Issued for an individually identified patient, consistent with section 503A compounding |
| Single active ingredient | The preparation contains only one active pharmaceutical ingredient from the policy's list, so a multi-peptide blend is not covered |
| Identity, route and form | For epitalon acetate: subcutaneous or intramuscular injectable forms, dispensed in intermittent courses |
| Source of the active ingredient | The original manufacturer, not a repackager or distributor, registered with the FDA and compliant with applicable CGMP requirements |
| Certificate of analysis | Lot-specific, stating the manufacturer's physical site, and meeting the conditions set out in Appendix B |
| Reporting | Serious adverse events and product quality problems reported to the FDA, with records of what was compounded |
| Labeling | The statement "This is a compounded drug product. Not for resale." |
| Device | Only a 510(k) cleared syringe may be co-packaged with or contain the preparation |
The single active ingredient condition deserves emphasis because it cuts against a common marketing pattern. Combination vials that put several peptides together in one container are not within the policy, even when each individual substance appears on the list of six. One container, one active ingredient.
The "intermittent courses" wording in Appendix B is also a limit rather than a description of a regimen. It is the dispensing pattern the appendix contemplates for epitalon acetate, and it is for the prescribing clinician to interpret within their own professional judgment. This article gives no amounts and no schedules, and no legitimate source should be giving you those on a web page.
Compliance with the full set of conditions is demanding in practice. Sourcing from an FDA-registered original manufacturer, maintaining certificate traceability lot by lot, and running adverse event reporting infrastructure are obligations with real cost. That is a useful filter: a pharmacy that cannot describe how it meets each condition probably does not meet them.
What does the policy require of the active ingredient and its certificate?
The sourcing condition is the heart of the document. The original manufacturer of the peptide bulk drug substance must be registered with the FDA under section 510 of the Federal Food, Drug, and Cosmetic Act and must comply with applicable current good manufacturing practice requirements, and the manufacturer's physical facility location must appear on the certificate of analysis. The word "original" is doing deliberate work here. A certificate issued by a repackager, a trading company or a distributor does not satisfy the condition, even if that intermediary is itself registered somewhere.
This is the condition most likely to fail quietly. Peptide active ingredient supply chains frequently involve several intermediaries between a synthesis site and a dispensing pharmacy, and a certificate can travel further than the accountability attached to it. If the document in front of a pharmacist does not name and locate the site that actually made the material, the preparation is not within the policy.
Appendix B then sets conditions on the certificate itself, and it is explicit that a document reporting a purity percentage alone would be insufficient. The appendix contemplates a substantive analytical record: identity and sequence confirmation, assay and content determinations, impurity testing, microbiological and endotoxin attributes, together with manufacturing and laboratory information, batch and dating details, storage conditions, and a designation that the material is for use in human drug compounding. Readers who want the precise test matrix should read Appendix B itself, because it is the operative document and it is short.
For a patient, this translates into one concrete request: ask whether the pharmacy holds a lot-specific certificate of analysis for the material used in your preparation, from the original manufacturer, and whether that certificate meets the Appendix B conditions. A pharmacy operating inside the policy will have that document and will be able to say where the material was made. The broader question of why analytical documentation matters so much for peptides is discussed in our article on peptide safety.
What reporting and labeling obligations apply?
Two of the conditions exist to make the arrangement observable rather than invisible. The first is reporting. Compounders within the policy are expected to report serious adverse events and product quality problems to the FDA, through the agency's MedWatch reporting system, as well as to the relevant state authorities, and to keep records of what they have compounded. This is the mechanism by which a problem with one of the six substances can become visible to the agency, and it is the same mechanism HHS points to when it says it may revisit the policy if a safety signal emerges.
That reporting duty has a direct consequence for anyone who receives such a preparation. If something unexpected happens, the pharmacy and the prescriber are the people who are supposed to escalate it, and they can only do that if they are told. Patients and clinicians may also submit reports to MedWatch themselves. A compounding route without reporting is not the route the policy describes.
The second condition is labeling. The container must bear the statement "This is a compounded drug product. Not for resale." The first sentence is a disclosure: it tells the person holding the vial that what they have was prepared by a pharmacy and has not been through FDA approval. The second sentence rules out onward sale.
For a reader, that label phrase is the single fastest authenticity check available. A product that is presented as compounded under the HHS policy but does not carry that statement is not labeled the way the policy requires. Equally, a vial carrying the statement still is not an approved medicine; the whole point of the phrase is to say so plainly.
Why does the policy mention only a 510(k) cleared syringe?
The policy addresses the delivery device separately from the drug, and it does so restrictively. The only device that may be co-packaged with, or contain, a compounded preparation under the policy is an FDA 510(k) cleared syringe. Nothing else is named.
The logic is regulatory rather than clinical. A syringe is a medical device in its own right and reaches the market through the 510(k) premarket notification pathway, where the FDA finds it substantially equivalent to a legally marketed predicate device. By limiting the permitted device to a cleared syringe, HHS keeps the device side of the package inside an existing review framework instead of extending enforcement discretion to a drug and a device at the same time.
On a plain reading of that text, delivery systems other than a cleared syringe fall outside the policy. That reading would exclude pre-filled pens, autoinjectors and cartridge-based systems, since none of them is a 510(k) cleared syringe and each raises its own device questions about dose-metering accuracy, container closure integrity and compatibility with a compounded solution. This is an interpretation of the wording rather than a quotation of an explicit prohibition, so a prescriber or pharmacist with a specific product in mind should read the condition in the policy itself before relying on it.
Note also what the condition does not do. It says nothing about technique, it authorizes nothing about how an injection should be performed, and it is not a statement that injection of this substance is appropriate for anyone. It is a packaging constraint on the pharmacy, and it should be read as one.
What is this policy not?
It is worth being blunt about the limits, because this is where most secondary coverage goes wrong. The policy is not an approval. No part of it reviews epitalon for safety or effectiveness, and no part of it authorizes a claim that it treats, prevents or improves anything. Approval requires an application, evidence and an agency decision, none of which has happened here.
It is also not a listing. Epitalon has not been added to the section 503A bulk drug substances list. The policy explicitly operates in the space before that question is settled: enforcement discretion for each substance is described as remaining in effect until that substance is addressed in a final rule as either included or not included on the list. If the final rule excludes epitalon, the basis for the current arrangement disappears.
It is interim and revocable. HHS states that it may revisit application of the interim policy, in whole or in part, if, among other things, a safety signal or a product quality issue arises with a compounded product within the scope of the policy. A patient beginning something on this basis should understand that the regulatory footing can change without any new legislation, and that the document itself says so.
And it is not a safe harbor. Enforcement discretion is a statement about what one federal department intends to do. It does not bind state regulators or state licensing boards, it does not resolve questions of professional liability or insurance coverage, and it does not create a defense that a compounder can simply assert. Nor does it change the status of the six substances under sport anti-doping rules, which operate independently of drug regulators.
Finally, the scientific objection has not been withdrawn. Appendix B itself records that CDER recommended against addition to the list for these substances. A policy that permits compounding while documenting that the agency's own reviewers found the evidence inadequate is not a vote of scientific confidence, and it should not be read as one.
What falls outside the policy entirely?
Three exclusions are explicit or structural, and together they define most of the real-world market.
Research use only material is not covered. The policy is concerned with compounding from active ingredient that meets its sourcing and certificate conditions. Vials labeled for research use only, not for human consumption, are the opposite of that: no prescription, no registered original manufacturer standing behind a compliant certificate, no required label statement, no reporting duty. HHS has framed the policy in part as an attempt to discourage the continued widespread use of research use only peptides supplied by foreign manufacturers by offering a more controlled alternative. The policy is therefore not a legitimization of that channel; its stated purpose runs the other way.
503B outsourcing facilities are not covered. The policy is about compounding under section 503A. Outsourcing facilities compounding under section 503B, which operate under CGMP and may prepare larger batches without patient-specific prescriptions, are outside its scope. Anyone relying on the policy should know which section their supplier operates under, because the answer determines whether the policy applies at all.
It changes nothing outside the United States. This is a United States federal policy addressed to United States compounders. It has no effect on the European Union, the United Kingdom, Canada, Australia, Switzerland or anywhere else, and it does not make importation into those jurisdictions lawful. National rules on unapproved medicines, on magistral and officinal preparation, and on personal importation continue to apply unchanged. Our legal status overview is the place to start for a jurisdiction other than the United States.
A fourth point is implicit but worth stating: the policy does not address any oral, nasal, topical or other non-injectable form of epitalon. Appendix B describes subcutaneous and intramuscular injectable forms dispensed in intermittent courses, and nothing beyond that.
What should you ask a clinician and a pharmacy?
If a prescriber raises this subject with you, or if you are considering raising it with them, the useful move is to ask questions that the policy itself makes answerable. The point is not to audit anyone. It is that a clinician and a pharmacy operating inside the policy will have ready answers, and that difficulty answering is informative.
Questions for the clinician:
- What specifically are you proposing to prescribe, in what form, and for what documented reason in my record?
- What is the evidence base in humans, and what did the FDA's own reviewers conclude about it?
- What are the known and unknown risks, and what would make you stop?
- What monitoring do you propose, and who follows up if something unexpected happens?
- What approved alternatives exist for the concern I came in with, and why are they not the first choice here?
- What happens to my care if the final rule excludes this substance from the 503A list?
- Who reports a serious adverse event, and to whom?
Questions for the pharmacy:
- Are you a state-licensed pharmacy compounding under section 503A, licensed in my state?
- Who is the original manufacturer of the active ingredient, is that manufacturer registered with the FDA, and does its physical site appear on the certificate of analysis?
- May I see the lot-specific certificate of analysis, and does it meet the conditions in Appendix B of the HHS policy?
- Does this preparation contain a single active ingredient only?
- What device is supplied with it, and is it a 510(k) cleared syringe?
- Does the label carry the statement "This is a compounded drug product. Not for resale."?
- What are the storage conditions and the beyond-use date, and how do you handle adverse event and product quality reporting?
Two closing points. First, nothing in this article is a recommendation to seek, accept or use a compounded epitalon preparation; the regulatory description above is not a clinical endorsement, and the FDA's reviewers reached a negative conclusion on the evidence. Second, the authoritative text is the HHS policy and its Appendix B, together with the Federal Register notice, all linked below. Where a summary and the primary document disagree, the primary document wins.
Educational content only. Not medical advice, and not a substitute for consultation with a qualified healthcare professional who knows your history. Epitalon is not approved by the FDA, legal status varies by jurisdiction, and most of the published evidence on this peptide is preclinical rather than clinical.
Recommended products
Research peptides selected for quality and purity:
Test your knowledge
Quick quiz · 6 questions
Frequently Asked Questions
Does the HHS policy mean epitalon is now an approved medicine in the United States?
Can a pharmacy put epitalon acetate and another peptide in the same vial under this policy?
Is a pre-filled pen covered by the HHS policy?
Does the policy apply to 503B outsourcing facilities?
How long will this enforcement discretion last?
Does this change anything for someone outside the United States?
Sources
- U.S. Department of Health and Human Services (2026). HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix B (substance-specific conditions, including epitalon acetate). HHS.gov. (hhs.gov)
- Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services (2026). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, Docket No. HHS-OASH-2026-0496). Federal Register. (federalregister.gov)
- U.S. Department of Health and Human Services (2026). HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (full policy document). HHS.gov. (hhs.gov)
- Rubin R (2026). Under FDA, Unapproved Peptides Likely to Become More Widely Available. JAMA. (PubMed)
- Moiz A, O'Keefe EL, O'Keefe JH (2026). Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Missouri Medicine. (PubMed)
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł (2025). Overview of Epitalon, a Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. (PMC)
- U.S. Food and Drug Administration (2026). Meeting of the Pharmacy Compounding Advisory Committee, July 23 and 24, 2026 (nominations of peptide bulk drug substances for the 503A list). FDA.gov. (fda.gov)
- U.S. Food and Drug Administration (2026). Human Drug Compounding Policies and Rules (sections 503A and 503B bulk drug substances lists). FDA.gov. (fda.gov)